Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions
Clinical practice is converging on early comprehensive genomic testing and prioritization of PARPi-based therapy for HRR-altered, especially BRCA1/2-mutated, prostate cancer. Key research priorities include functional biomarkers beyond gene panels, rational combinations to prevent/overcome resistance, and optimized sequencing across disease states.
Authors
- A. Hussain
- Samer Rifai
- Zumar Meher
- Xiaolei Shi
Institutions
- University of Maryland, Baltimore (US)
- Baltimore VA Medical Center (US)
- U-M Rogel Cancer Center (US)
Publication Details
- Journal
- Current Opinion in Oncology
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1097/cco.0000000000001230
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00